explore -WSS

explore

author：entertainment 2025-09-30 17:43:52 - browse：112

This image provided by Amylyx Pharmaceuticals shows the drug Relyvrio. The maker of a much-debated drug for Lou Gehrig’s disease said Friday, March 8, 2024 its therapy failed to help patients in a large follow-up study, but stopped short of committing to follow through on a prior pledge to pull the drug from the U.S. market. — Relyvrio, an ALS drug made by Amylyx Pharmaceuticals, failed to beat placebo in a key clinical trial. Amylyx Pharmaceuticals via AP

The latest disappointment in amyotrophic lateral sclerosis research brought crushing news for patients and physicians, forcing the community to consider just what to do with an approved medicine that doesn’t appear to work.

Amylyx Pharmaceuticals’ announcement Friday that its drug, marketed as Relyvrio, failed to beat placebo in a pivotal study marks “a sad day for us, but we have to believe the data,” said Mary Catherine Collet, an ALS advocate. “These are hard scientific facts that we have to face, and I appreciate that they’re not trying to spin us like some cheerleading practice.”

The question now is whether Relyvrio, approved in 2022, should be removed from the market entirely — and whether the Food and Drug Administration made a mistake by authorizing it in the first place. After years of pressure from patient advocates, the agency has taken a more flexible approach to medicines for devastating, incurable diseases like ALS. But the case of Relyvrio, which made $381 million in sales and $49 million in profit for Amylyx last year, has underlined questions about the limits of regulatory leniency.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical records are filled with copy
Next article： Zyn nicotine pouches become unlikely player in latest culture war

knowledge

WSS

Humana’s losses in Medicare Advantage tank its stock

Humana’s losses in Medicare Advantage tank its stock

Brain injuries and the importance of a second opinion

Readout Newsletter: Medeor's stem cell study, Moderna's stock dip

Lung cancer screening guidelines updated for cigarette smokers

Vertex non

explore

explore

entertainment

Apple is now the first public company to be valued at $3 trillion

Bernie Sanders is gearing up to subpoena pharma CEOs

United colonoscopy coverage change 'may cost lives,' doctors say

The Affordable Care Act has saved billions in health care costs

Guidelines to prevent youth baseball injuries need more muscle

Zyn nicotine pouches become unlikely player in latest culture war

Guidelines to prevent youth baseball injuries need more muscle

Wegovy leads to weight loss. Can it treat depression, too?

New air purifier tech could be key to improving indoor air quality

Why Medicare shouldn’t cover every FDA

explore

Gene therapy’s promise and the high cost of hope

Philips to halt sales of sleep apnea machines in U.S.

Infant mortality in U.S. rose last year for first time in decades: CDC

How generative AI ratchets up security threats for health systems

DeepMind touts AlphaFold's new skills as protein folding AI models face off

Kidney transplant patients stopped immunosuppressants in trial

Wikipedia

Wikipedia

knowledge

focus